Morgan Stanley Portfolio holdings
Morgan Stanley, founded in 1935 by Henry Sturgis Morgan and Harold Stanley as a spin-off from J.P. Morgan & Co., is a leading global financial services firm headquartered in New York City. Initially focused on investment banking, it has evolved into a diversified powerhouse offering wealth management, institutional securities, and asset management services, catering to corporations, governments, institutions, and high-net-worth individuals. With a strong presence in mergers and acquisitions, underwriting, and trading, Morgan Stanley manages billions in assets and is known for its sophisticated financial advisory services. The firm has adapted to modern markets by expanding its digital offerings and wealth management division, notably through its 2020 acquisition of E*TRADE, solidifying its position as a Wall Street titan.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.77B |
| 2 |
McKesson
MCK
|
+$2.38B |
| 3 |
SpaceX
SPCX
|
+$2.3B |
| 4 |
HONA
Honeywell Aerospace
HONA
|
+$2.05B |
| 5 |
Amazon
AMZN
|
+$1.37B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$5.96B |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$3.11B |
| 3 |
Honeywell
HON
|
+$1.96B |
| 4 |
Salesforce
CRM
|
+$1.47B |
| 5 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$775M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.02% |
| 2 | Technology | 24.63% |
| 3 | Financials | 9.78% |
| 4 | Healthcare | 7.32% |
| 5 | Industrials | 7.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4976
Pacer Trendpilot US Bond ETF
PTBD
$84.5M
| $1.31M | ﹤0.01% |
68,394
-10,684
| -14% | -$205K |
2021 Q1
21 quarters
|
|
4977
Invesco Food & Beverage ETF
PBJ
$108M
| $1.31M | ﹤0.01% |
27,807
+1,883
| +7% | +$91.6K |
2013 Q2
52 quarters
|
|
4978
Bright Minds Biosciences
DRUG
$515M
| $1.31M | ﹤0.01% |
18,599
-114,165
| -86% | -$8.96M |
2024 Q4
6 quarters
|
|
4979
MediWound
MDWD
$154M
| $1.3M | ﹤0.01% |
88,660
+187
| +0.2% | +$2.97K |
2018 Q3
31 quarters
|
|
4980
Matthews Emerging Markets Sustainable Future Active ETF
EMSF
$44.1M
| $1.3M | ﹤0.01% |
30,665
| – | – |
2025 Q3
3 quarters
|
|
4981
Special Opportunities Fund
SPE
$136M
| $1.3M | ﹤0.01% |
96,684
+5,922
| +7% | +$82.8K |
2013 Q2
52 quarters
|
|
4982
Weibo
WB
$1.6B
| $1.3M | ﹤0.01% |
179,106
-53,284
| -23% | -$435K |
2014 Q2
48 quarters
|
|
4983
Candel Therapeutics
CADL
$642M
| $1.3M | ﹤0.01% |
126,145
+67,916
| +117% | +$513K |
2024 Q2
8 quarters
|
|
4984
Blaize Holdings
BZAI
$37.5M
| $1.3M | ﹤0.01% |
940,787
+28,011
| +3% | +$49.3K |
2025 Q1
5 quarters
|
|
4985
Aldeyra Therapeutics
ALDX
$40.8M
| $1.3M | ﹤0.01% |
608,321
+89,679
| +17% | +$154K |
2014 Q4
46 quarters
|
|
4986
Northern Trust Morningstar Emerging Markets Factor Tilt ETF
TLTE
$335M
| $1.29M | ﹤0.01% |
16,693
-81
| -0.5% | -$6.12K |
2013 Q4
50 quarters
|
|
4987
Concrete Pumping Holdings
BBCP
$462M
| $1.29M | ﹤0.01% |
107,091
+34,446
| +47% | +$296K |
2018 Q2
32 quarters
|
|
4988
Ceragon Networks
CRNT
$188M
| $1.28M | ﹤0.01% |
495,795
+15,553
| +3% | +$40.7K |
2013 Q2
52 quarters
|
|
4989
Clough Global Dividend & Income Fund
GLV
$72M
| $1.28M | ﹤0.01% |
192,749
+6,038
| +3% | +$37.7K |
2013 Q2
52 quarters
|
|
4990
Invesco CurrencyShares Australian Dollar Trust
FXA
$92.8M
| $1.28M | ﹤0.01% |
18,610
-979
| -5% | -$68.9K |
2013 Q2
52 quarters
|
|
4991
Treace Medical Concepts
TMCI
$258M
| $1.27M | ﹤0.01% |
320,026
+100,319
| +46% | +$276K |
2021 Q2
20 quarters
|
|
4992
Kailera Therapeutics
KLRA
$1.5B
| $1.27M | ﹤0.01% |
+57,786
| New | +$1.27M |
2026 Q2
0 quarters
|
|
4993
SOLV Energy Inc
MWH
$4.81B
| $1.27M | ﹤0.01% |
37,162
-6,876
| -16% | -$249K |
2026 Q1
1 quarter
|
|
4994
Shattuck Labs
STTK
$542M
| $1.26M | ﹤0.01% |
181,712
-18,424
| -9% | -$115K |
2020 Q4
22 quarters
|
|
4995
Kingstone Companies
KINS
$272M
| $1.26M | ﹤0.01% |
66,207
-50,560
| -43% | -$815K |
2024 Q2
8 quarters
|
|
4996
OBOOK Holdings
OWLS
$386M
| $1.26M | ﹤0.01% |
222,160
+418
| +0.2% | +$2.43K |
2025 Q4
2 quarters
|
|
4997
Principal Capital Appreciation Select ETF
LCAP
$1.89B
| $1.25M | ﹤0.01% |
37,799
-22,685
| -38% | -$727K |
2025 Q3
3 quarters
|
|
4998
AIRO Group Holdings
AIRO
$168M
| $1.25M | ﹤0.01% |
168,948
+25,195
| +18% | +$197K |
2025 Q2
4 quarters
|
|
4999
AAM Crescent CLO ETF
CLOC
$61.4M
| $1.25M | ﹤0.01% |
+50,000
| New | +$1.25M |
2026 Q2
0 quarters
|
|
5000
Zai Lab
ZLAB
$2.68B
| $1.24M | ﹤0.01% |
65,401
-28,996
| -31% | -$573K |
2017 Q3
35 quarters
|
|
Similar funds
Morgan Stanley's Q2 2026 Portfolio in Review
As of Q2 2026, Morgan Stanley held 8,715 positions worth $1.89T, up 14% from $1.66T the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Morgan Stanley's Q2 2026 filing shows 425 new, 3,807 increased, 3,215 reduced and 303 closed positions. Its largest new stake was SpaceX: 13,532,773 shares worth $2.31B. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $5.96B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 27% a quarter earlier, followed by Technology and Financials.
- Morgan Stanley's largest Q2 2026 buy was SpaceX: 13,532,773 shares worth $2.31B.
- Morgan Stanley added most to NVIDIA in Q2 2026, an estimated $2.77B increase.
- Morgan Stanley's biggest Q2 2026 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $5.96B.
- Morgan Stanley fully exited Apellis Pharmaceuticals in Q2 2026, selling an estimated $404M.
- Morgan Stanley's ten largest holdings make up 21% of its $1.89T portfolio in Q2 2026.
- Morgan Stanley opened 425 new positions and closed 303 in Q2 2026.
- Morgan Stanley's portfolio value rose 14% quarter-over-quarter to $1.89T.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.